Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 10, 2020 02:00 ET | Source: Atox Bio

Atox Bio Announces a Positive Effect of Reltecimod on Resolution of Organ Dysfunction in Phase 3 ACCUTE Trial for Patients with Necrotizing Soft Tissue Infection (“Flesh Eating Disease”)

- After Discussions with FDA, NDA Submission Planned for 3Q 2020 under Accelerated Approval Pathway - Reltecimod in conjunction with currently available standard of care demonstrated a significant...